Monopar Therapeutics (MNPR) Long-Term Investments (2022 - 2025)

Monopar Therapeutics (MNPR) has 4 years of Long-Term Investments data on file, last reported at $78.6 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments rose 445.75% year-over-year to $78.6 million; the trailing twelve-month figure through Dec 2025 stood at $78.6 million (up 445.75% YoY), and the FY2025 full-year result was $78.6 million, up 445.75% from the prior year.
• Long-Term Investments climbed to $78.6 million in Q4 2025, from $16.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $78.6 million in Q4 2025 to a low of $985730.0 in Q1 2024.
• A 4-year average of $14.2 million and a median of $6.0 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments slumped 83.43% in 2024 and soared 1405.61% in 2025, its largest moves.
• Tracing MNPR's Long-Term Investments over 4 years: stood at $4.9 million in 2022, then tumbled by 39.61% to $3.0 million in 2023, then surged by 383.17% to $14.4 million in 2024, then jumped by 445.75% to $78.6 million in 2025.
• Business Quant data shows MNPR's Long-Term Investments at $78.6 million in Q4 2025, $16.0 million in Q3 2025, and $13.7 million in Q2 2025.